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patients had a prescription ﬁlled for a beta-blocker during 2002.
Of the CHF patients receiving a beta-blocker, less than 45% were
prescribed either of the two indicated agents (carvedilol or
extended-release metoprolol succinate) for CHF. Furthermore,
less than 40% of patients prescribed either carvedilol or
extended-release metoprolol succinate achieved target CHF
doses. Thus, of those CHF patients currently on beta-blocker
therapy, less than 17% received an appropriate regimen. CON-
CLUSIONS: This evaluation illustrates that less than ten percent
of CHF patients in this managed care plan are receiving optimal
beta-blocker therapy. Future quality improvement efforts should
be focused on provider-based educational initiatives to improve
beta-blocker prescribing patterns in the CHF population.
Increased use of beta-blocker therapy in patients identiﬁed with
CHF would signiﬁcantly improve the morbidity and mortality
associated with this disease.
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OBJECTIVES: To investigate statin usage patterns in terms of
termination, switch and/or augmentation, and to associate these
patterns with changing market conditions. METHODS: The
study is based on a 20% sample of California Medicaid (Medi-
Cal) fee-for-service claims on statin prescriptions from 1995
through 2002. The length of the ﬁrst statin therapy phase is pre-
sented with Kaplan-Meier curves. The switch and/or augmenta-
tion pattern is studied by tracking each patient for 12 months
from the date of the ﬁrst ﬁll (index date). Results are presented
by the year of index date. There are six statins included in the
study: Cerivastatin, Fluvastatin, Atorvastatin, Lovastatin,
Pravastatin and Simvastatin. RESULTS: Atorvastatin (N =
15,686, Median survival days = 244) and Simvastatin (N = 9162,
Median survival days = 200) had longer therapy phases while
Cerivastatin (N = 2022, Median survival days = 101) and Lovas-
tatin (N = 8910, Median survival days = 99) had shorter therapy
phases. About 40% of Atorvastatin and Simvastatin patients
were still on their initial medication after one year, but only 20%
of patients initiated on Lovastatin or Cerivastatin remained on
their medication. The introduction of Atorvastatin was associ-
ated with a sudden increase of switch/augmentation events
among patients initiated on other statin brands. When Cerivas-
tatin was withdrawn from the US market and Lovastatin was
phased out of the Medi-Cal formulary, the proportion of
switch/augmentation events also increased. CONCLUSIONS:
The introduction of Atorvastatin, the withdrawal of Cerivastatin
and the phase-out of Lovastatin may be key factors in statin per-
sistence patterns. Market forces should not be overlooked when
analyzing medication compliance and medication usage patterns.
Because changes in the market are more likely to be unique
events, their effect may overshadow other adjustments in 
comparison of medication compliance.
PCV53
IMPACT OF THE ANTIHYPERTENSIVE AND LIPID-LOWERING
TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
ON PHYSICIAN PRESCRIBING PATTERNS AND PATIENT
UTILIZATION OF ANTIHYPERTENSIVE MEDICATIONS
Liu X,Yu W,Yokoyama K
WellPoint Pharmacy Management, West Hills, CA, USA
OBJECTIVES: To analyze the changes in utilization and pre-
scribing patterns of antihypertensive drugs before and after the
publication of the ALLHAT results in 2002 that recommended
the use of thiazide diuretics in new starts. METHODS: Utilizing
pharmacy claims, member and provider data from a managed
care plan of over 2 million members, this study selected two
cohorts of patients who received two or more claims for anti-
hypertensive or diuretic products from the same providers in the
ﬁrst 9 months of 2002 (Period 1) or the ﬁrst 9 months of 2003
(Period 2). The providers who prescribed antihypertensive or
diuretic medications for both periods were included. The patients
were continuously enrolled adults who did not receive any anti-
hypertensive or diuretic products in the 3 months prior to index
date. Changes in physician prescribing patterns for initiation of
hypertension treatment in Period 1 and Period 2 were analyzed.
Utilization of different medications between the two periods,
especially the likelihood of receiving thiazide diuretics, was also
examined. RESULTS: The study identiﬁed 7605 physicians who
prescribed antihypertensive drugs to 25,519 patients in Period 1
and 26,300 patients in Period 2. Across the two periods, the per-
centage of physicians who prescribed any thiazide diuretics
increased from 14.5% to 16.1% (p < 0.01), while utilization of
ACE inhibitors or CCBs as initial treatment decreased approxi-
mately 2% (p < 0.01). A logistic regression model indicated that
patients in Period 2 were 22.8% more likely to receive thiazide
diuretics and 9.9% more likely to receive any diuretics than
patients in Period 1 (p < 0.01), controlling for demographics,
comorbidities measured by chronic disease scores (CDS), 
and provider specialties. CONCLUSION: ALLHAT results
increased prescribing of thiazide diuretics as initial treatment of
hypertension.
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OBJECTIVE: The NSF guidelines for CAD, introduced in March
2000 in the UK, advocate that by April 2002, 80–90% of the
patients discharged from hospital following myocardial infarc-
tion (MI) should be receiving prescriptions for aspirin and statins
for secondary prevention. A time-trend analysis was performed
to assess the impact of NSF on physician compliance with the
prescribing guidelines. METHODS: The UK-Mediplus, a nation-
ally representative general-practitioner database was used to
identify all individuals with diagnosis of their ﬁrst MI (index-
date) between April 1997 and March 2003, and surviving at least
90 days following the index-date. Patients receiving at least one
prescription of statin and aspirin, linked to their MI diagnosis,
during the 90-day follow-up period were considered NSF-com-
pliant with those drugs respectively. Annual trends in proportion
of NSF-compliant patients, for aspirin, statins and aspirin-statin
combination, were compared between pre- and post-NSF (after
March 2000) periods. Logistic regression was used to estimate
the effect of age and gender on compliance. RESULTS: Of 8598
eligible ﬁrst-MI patients with a mean age of 70.4 (S.D. = 13.2),
65.5% were males, and 67.2% were elderly (age 65+). Aspirin-
statin combination use increased from 13.7% to 23.5% between
April 1997 and March 2000, and increased to 42.1% by March
2003. Aspirin and statin use alone were 49.5% and 71.6%
respectively by end of March 2003. Relative to non-elderly, the
elderly were less likely to receive aspirin-statin combination.
However, the odds ratio (OR) for the elderly receiving combi-
nation improved during post-NSF period (OR = 0.64, p < 0.05
